Acute allograft rejection in human liver transplant recipients is associated with signaling through toll-like receptor 4

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 1, 2011, Pages 155-163

  Testro, Adam G ^a,b   Visvanathan, Kumar ^c   Skinner, Narelle ^c   Markovska, Vesna ^c   Crowley, Peter ^b   Angus, Peter W ^a,b   Gow, Paul J ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Victorian Liver Transplant Unit   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Damage associated molecular patterns; Inflammation; Innate immunity; Liver; Rejection

Indexed keywords

CYCLOSPORIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TACROLIMUS; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT REJECTION; ADULT; ALLOIMMUNITY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MONOCYTE; NONALCOHOLIC FATTY LIVER; PERIPHERAL BLOOD MONONUCLEAR CELL; POSTOPERATIVE PERIOD; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 78650335642     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06324.x     Document Type: Article

References (49)

1. Eksteen B, Neuberger JM. Mechanisms of disease: the evolving understanding of liver allograft rejection. Nat. Clin. Pract. Gastroenterol. Hepatol. 2008; 5: 209-19.
2. Albiger B, Dahlberg S, Henriques-Normark B, Normark S. Role of the innate immune system in host defence against bacterial infections: focus on the Toll-like receptors. J. Intern. Med. 2007; 261: 511-28.
3. Riordan SM, Skinner N, Nagree A et al. Peripheral blood mononuclear cell expression of Toll-like receptors and relation to cytokine levels in cirrhosis. Hepatology 2003; 37: 1154-64.
4. Medzhitov R, Janeway C Jr. Innate immunity. N. Engl. J. Med. 2000; 343: 338-44.
5. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2001; 2: 675-80.
6. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J. Immunol. 1999; 163: 1-5.
7. Kol A, Bourcier T, Lichtman AH, Libby P. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J. Clin. Invest. 1999; 103: 571-7.
8. Sasu S, LaVerda D, Qureshi N, Golenbock DT, Beasley D. Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via Toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ. Res. 2001; 89: 244-50.
9. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex. J. Immunol. 2000; 164: 558-61.
10. Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J. Biol. Chem. 2002; 277: 15107-12.
11. Beg AA. Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol. 2002; 23: 509-12.
12. Land WG. The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. Transplantation 2005; 79: 505-14.
13. Zhai Y, Shen XD, O'Connell R et al. Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J. Immunol. 2004; 173: 7115-19.
14. Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat. Immunol. 2004; 5: 975-9.
15. Palmer SM, Burch LH, Davis RD et al. The role of innate immunity in acute allograft rejection after lung transplantation. Am. J. Respir. Crit. Care Med. 2003; 168: 628-32.
16. Ducloux D, Deschamps M, Yannaraki M et al. Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney Int. 2005; 67: 2454-61.
17. Methe H, Zimmer E, Grimm C, Nabauer M, Koglin J. Evidence for a role of Toll-like receptor 4 in development of chronic allograft rejection after cardiac transplantation. Transplantation 2004; 78: 1324-31.
18. Goldberg A, Parolini M, Chin BY et al. Toll-like receptor 4 suppression leads to islet allograft survival. FASEB J. 2007; 21: 2840-8.
19. Jiang J, Arp J, Kubelik D et al. Induction of indefinite cardiac allograft survival correlates with Toll-like receptor 2 and 4 downregulation after serine protease inhibitor-1 (Serp-1) treatment. Transplantation 2007; 84: 1158-67.
20. Hanck C, Manigold T, Bocker U et al. Gene expression of interleukin 18 in unstimulated peripheral blood mononuclear cells of patients with alcoholic cirrhosis. Gut 2001; 49: 106-11.
21. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658-63.
22. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol. 2001; 2: 947-50.
23. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001; 106: 255-8.
24. Kaisho T, Akira S. Dendritic-cell function in Toll-like receptor- and MyD88-knockout mice. Trends Immunol. 2001; 22: 78-83.
25. Buttenschoen K, Buttenschoen DC, Berger D et al. Endotoxemia and acute-phase proteins in major abdominal surgery. Am. J. Surg. 2001; 181: 36-43.
26. Abdala E, Baia CE, Mies S et al. Bacterial translocation during liver transplantation: a randomized trial comparing conventional with venovenous bypass vs. piggyback methods. Liver Transpl. 2007; 13: 488-96.
27. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu. Rev. Immunol. 2003; 21: 685-711.
28. Coates PT, Duncan FJ, Colvin BL et al. In vivo-mobilized kidney dendritic cells are functionally immature, subvert alloreactive T-cell responses, and prolong organ allograft survival. Transplantation 2004; 77: 1080-9.
29. Jennings C, Kusler B, Jones PP. Calcineurin inactivation leads to decreased responsiveness to LPS in macrophages and dendritic cells and protects against LPS-induced toxicity in vivo. Innate Immun. 2009; 15: 109-20.
30. West MA, Heagy W. Endotoxin tolerance: a review. Crit. Care Med. 2002; 30: S64-73.
31. Sanchez-Cantu L, Rode HN, Christou NV. Endotoxin tolerance is associated with reduced secretion of tumor necrosis factor. Arch. Surg. 1989; 124: 1432-5; discussion 1435-6.
32. Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of Toll-like receptor-mediated immune responses. Nat. Rev. Immunol. 2005; 5: 446-58.
33. Wald D, Qin J, Zhao Z et al. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat. Immunol. 2003; 4: 920-7.
34. Brint EK, Xu D, Liu H et al. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat. Immunol. 2004; 5: 373-9.
35. Divanovic S, Trompette A, Atabani SF et al. Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat. Immunol. 2005; 6: 571-8.
36. Nakagawa R, Naka T, Tsutsui H et al. SOCS-1 participates in negative regulation of LPS responses. Immunity 2002; 17: 677-87.
37. Kobayashi K, Hernandez LD, Galan JE, Janeway CA Jr, Medzhitov R, Flavell RA. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002; 110: 191-202.
38. Kinjyo I, Hanada T, Inagaki-Ohara K et al. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity 2002; 17: 583-91.
39. Burns K, Janssens S, Brissoni B, Olivos N, Beyaert R, Tschopp J. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J. Exp. Med. 2003; 197: 263-8.
40. Miggin SM, O'Neill LA. New insights into the regulation of TLR signaling. J. Leukoc. Biol. 2006; 80: 220-6.
41. Doyle SL, O'Neill LA. Toll-like receptors: from the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity. Biochem. Pharmacol. 2006; 72: 1102-13.
42. Lepe-Zuniga JL, Klostergaard J. Tolerance to endotoxin in vitro: independent regulation of interleukin-1, tumor necrosis factor and interferon alpha production during in vitro differentiation of human monocytes. Lymphokine Res. 1990; 9: 309-19.
43. Mathison JC, Virca GD, Wolfson E, Tobias PS, Glaser K, Ulevitch RJ. Adaptation to bacterial lipopolysaccharide controls lipopolysaccharide-induced tumor necrosis factor production in rabbit macrophages. J. Clin. Invest. 1990; 85: 1108-18.
44. Medvedev AE, Kopydlowski KM, Vogel SN. Inhibition of lipopolysaccharide-induced signal transduction in endotoxin-tolerized mouse macrophages: dysregulation of cytokine, chemokine, and Toll-like receptor 2 and 4 gene expression. J. Immunol. 2000; 164: 5564-74.
45. Lin CY, Tsai IF, Ho YP et al. Endotoxemia contributes to the immune paralysis in patients with cirrhosis. J. Hepatol. 2007; 46: 816-26.
46. von Baehr V, Docke WD, Plauth M et al. Mechanisms of endotoxin tolerance in patients with alcoholic liver cirrhosis: role of interleukin 10, interleukin 1 receptor antagonist, and soluble tumour necrosis factor receptors as well as effector cell desensitisation. Gut 2000; 47: 281-7.
47. Heller J, Sogni P, Barriere E et al. Effects of lipopolysaccharide on TNF-alpha production, hepatic NOS2 activity, and hepatic toxicity in rats with cirrhosis. J. Hepatol. 2000; 33: 376-81.
48. Ramirez MJ, Ibanez A, Navasa M et al. High-density lipoproteins reduce the effect of endotoxin on cytokine production and systemic hemodynamics in cirrhotic rats with ascites. J. Hepatol. 2004; 40: 424-30.
49. Testro AG, Gow PJ, Skinner NA et al. Effects of antibiotics on expression and function of toll-like receptors 2 and 4 on mononuclear cells in patients with advanced cirrhosis. J. Hepatol. 2010; 52: 199-205.